Related Experiment Video

Updated: Mar 7, 2026

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
11:10

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation

Published on: July 6, 2022

2.7K

Retracted: Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566

R M J Deacon1,2,3, M J Hurley3,4, C M Rebolledo5

  • 1Biomedicine Division, Centre for Systems Biotechnology, Fraunhofer Research Foundation, Santiago, Chile.

Genes, Brain, and Behavior
|February 18, 2017
PubMed

Insights

This study on Nrf2 as a therapeutic target for fragile X syndrome, modulated by NNZ2566, has been retracted due to author disagreements on order. The article is no longer available for publication.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Fragile X syndrome (FXS) is a genetic disorder causing intellectual disability and developmental challenges.
  • Nuclear factor erythroid 2-related factor 2 (Nrf2) plays a role in cellular defense and has been implicated in neurological disorders.
  • NNZ2566 is an experimental compound investigated for potential therapeutic effects.

Purpose of the Study:

  • To investigate the role of Nrf2 as a potential therapeutic target in fragile X syndrome.
  • To determine if NNZ2566 modulates Nrf2 activity in the context of fragile X syndrome.

Main Methods:

  • The study involved investigating the modulation of Nrf2 by NNZ2566.
  • Specific experimental details regarding the methods used are not available due to the retraction.

Main Results:

  • The article reported findings on the modulation of Nrf2 by NNZ2566 in relation to fragile X syndrome.
  • Specific results are not available due to the retraction.

Conclusions:

  • The original article suggested Nrf2 as a potential therapeutic target for fragile X syndrome.
  • The findings and conclusions are no longer considered valid due to the retraction.

More Related Videos

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

8.5K
Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein10:59

Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein

Published on: June 6, 2025

1.2K

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
4.3K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
3.1K